By promoting close cooperation between basic science and clinical research, the Cluster aims to more rapidly transfer findings from basic research to clinical application. To facilitate this process, NeuroCure has established its own clinical research center (NCRC) within the Charité – Universitätsmedizin Berlin. The NCRC supports researchers in conducting clinical trials, and gives patients access to new therapies and diagnostic options through participation in clinical trials.

At the beginning of 2019, NeuroCure entered its third round of funding within the Excellence Strategy framework. In this new phase of funding, the cluster is bringing together 23 excellent scientists, each working at the top of their fields in selected research areas that have the potential to transform both basic and translational neuroscience.

In line with our commitment to narrowing the gap between basic and clinical neuroscience, we are providing tailored programs and creating new structures to foster communication between basic researchers and clinicians. Our goal is to support collaboration and facilitate an exchange of expertise and methodologies that will promote the development of successful therapies and diagnostic tools.

In the future, we plan to focus on collaborative projects in three areas of neuroscientific research: development, maintenance and aging. Rather than restrict our focus to a specific

To support our research, we have also established new translational modules: NCRC-BrainLab provides researchers with increased access to patients, including inpatients with acute and severe brain disorders; SPARK aims to accelerate and improve the translation process; and VOS – Value and Open Science strengthens the predictive power of our research, thereby improving the translational pipeline.

Our goal is to create a research environment at the forefront of translational neuroscience. NeuroCure’s new generation of programs and structures, each tailored specifically towards facilitating relevant clinical advances, moves us closer to this goal, making our already highly collaborative research environment even stronger.

brain disease, our overarching aim is to elucidate overlapping pathophysiological processes that can be found in multiple neurological and psychiatric disorders.

Involved Institutions:

• Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) im Forschungsverbund Berlin e.V.
• Max-Delbrück-Centrum für Molekulare Medizin (MDC)
• Max-Planck-Forschungsstelle für die Wissenschaft der Pathogene
• Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) c/o Charité – Universitätsmedizin Berlin